|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CURRENT ASSETS: | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Short-term investment in equity securities, at fair value | ||||||||||||||||||||
| Prepaid and other current assets | ||||||||||||||||||||
| Notes receivable | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right-of-use assets | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Investment in equity securities, at fair value | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Promissory note | ||||||||||||||||||||
| Convertible note | ||||||||||||||||||||
| Other short-term loan | ||||||||||||||||||||
| Contract liabilities | ||||||||||||||||||||
| Current portion of operating lease liability | ||||||||||||||||||||
| Current portion of COVID loan | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term portion of operating lease liability | ||||||||||||||||||||
| Long-term portion of COVID loan | ||||||||||||||||||||
| Estimate fair value | ||||||||||||||||||||
| Long-term portion of promissory note | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Defined benefit plan obligation | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY: | ||||||||||||||||||||
| Preferred Stock | ||||||||||||||||||||
| Series F Convertible Preferred Stock | ||||||||||||||||||||
| Series G Convertible Preferred Stock | ||||||||||||||||||||
| Total preferred Stock | ||||||||||||||||||||
| Common Stock, $0.001 par value, 200,000,000 shares authorized, 62,103,454 and 43,613,800 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
